Marcin P. Cieslik

This paper develops an immunocompetent mouse model of Merkel cell carcinoma that forms tumors and metastases, showing that LSD1 inhibitors effectively reduce tumor growth and metastasis.

This study uses FFPE-compatible Hi-C to detect enhancer-hijacking rearrangements in lymphoid cancers, identifying clinically relevant drivers missed by standard methods.

The paper compiles and provides eight scRNA-seq datasets from nine cancer types, 174 patients, and 90,270 cancer cells to study ICB treatment responses.

This study shows CDK12 loss drives prostate cancer development and identifies CDK13 as a therapeutic target through paralog-based synthetic lethality in CDK12-mutant tumors.

This study shows that PIKfyve inhibition enhances dendritic cell function and improves immunotherapy efficacy in tumor models.

HLAProphet improves HLA protein quantification by using personalized allele information from DNA sequencing, increasing peptide identifications and aligning with RNA expression and loss of heterozygosity.

MHCnvex is a likelihood-based model for accurately calling copy number variations and loss of heterozygosity in MHC class I and II loci, improving accuracy by integrating adjacent chromosome 6 regions.